Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curtis K Johnston

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|November 29, 2023
Bayesian estimation in NONMEMCurtis K Johnston, Timothy Waterhouse, Matthew Wiens, et al.
Pharmaceutics|April 30, 2021
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 DiabetesCurtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, et al.
Digestive Diseases and Sciences|July 4, 2015
Altered Bile Acid Metabolome in Patients with Nonalcoholic SteatohepatitisBrian C Ferslew, Guoxiang Xie, Curtis K Johnston, et al.
Diabetes, Obesity & Metabolism|December 21, 2019
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacyBruce A Perkins, Nima Soleymanlou, Julio Rosenstock, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|November 29, 2023
Bayesian estimation in NONMEMCurtis K Johnston, Timothy Waterhouse, Matthew Wiens, et al.
Pharmaceutics|April 30, 2021
A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 DiabetesCurtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, et al.
Digestive Diseases and Sciences|July 4, 2015
Altered Bile Acid Metabolome in Patients with Nonalcoholic SteatohepatitisBrian C Ferslew, Guoxiang Xie, Curtis K Johnston, et al.
Diabetes, Obesity & Metabolism|December 21, 2019
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacyBruce A Perkins, Nima Soleymanlou, Julio Rosenstock, et al.
Pageof 1